Bifogade filer
Prenumeration
Kalender
Est. tid* | ||
2026-11-05 | 08:00 | Kvartalsrapport 2026-Q3 |
2026-08-27 | 08:00 | Kvartalsrapport 2026-Q2 |
2026-05-21 | N/A | Årsstämma |
2026-05-13 | 08:00 | Kvartalsrapport 2026-Q1 |
2026-02-19 | 08:00 | Bokslutskommuniké 2025 |
2025-11-05 | 08:00 | Kvartalsrapport 2025-Q3 |
2025-08-21 | - | Kvartalsrapport 2025-Q2 |
2025-05-23 | - | X-dag ordinarie utdelning ONCO 0.00 SEK |
2025-05-22 | - | Årsstämma |
2025-05-15 | - | Kvartalsrapport 2025-Q1 |
2025-02-27 | - | Bokslutskommuniké 2024 |
2024-11-07 | - | Kvartalsrapport 2024-Q3 |
2024-08-14 | - | Kvartalsrapport 2024-Q2 |
2024-05-30 | - | Kvartalsrapport 2024-Q1 |
2024-05-23 | - | X-dag ordinarie utdelning ONCO 0.00 SEK |
2024-05-22 | - | Årsstämma |
2024-04-15 | - | Extra Bolagsstämma 2024 |
2024-02-27 | - | Bokslutskommuniké 2023 |
2023-11-08 | - | Kvartalsrapport 2023-Q3 |
2023-08-10 | - | Kvartalsrapport 2023-Q2 |
2023-05-26 | - | X-dag ordinarie utdelning ONCO 0.00 SEK |
2023-05-25 | - | Årsstämma |
2023-05-04 | - | Kvartalsrapport 2023-Q1 |
2023-02-16 | - | Bokslutskommuniké 2022 |
2022-11-09 | - | Kvartalsrapport 2022-Q3 |
2022-09-23 | - | Extra Bolagsstämma 2022 |
2022-08-11 | - | Kvartalsrapport 2022-Q2 |
2022-06-28 | - | Årsstämma |
2022-05-20 | - | X-dag ordinarie utdelning ONCO 0.00 SEK |
2022-05-04 | - | Kvartalsrapport 2022-Q1 |
2022-02-17 | - | Bokslutskommuniké 2021 |
2021-11-24 | - | Kvartalsrapport 2021-Q3 |
2021-08-19 | - | Kvartalsrapport 2021-Q2 |
2021-05-27 | - | X-dag ordinarie utdelning ONCO 0.00 SEK |
2021-05-26 | - | Årsstämma |
2021-05-26 | - | Kvartalsrapport 2021-Q1 |
2021-02-18 | - | Bokslutskommuniké 2020 |
2020-12-04 | - | Extra Bolagsstämma 2020 |
2020-11-19 | - | Kvartalsrapport 2020-Q3 |
2020-08-26 | - | Kvartalsrapport 2020-Q2 |
2020-05-27 | - | X-dag ordinarie utdelning ONCO 0.00 SEK |
2020-05-26 | - | Årsstämma |
2020-05-26 | - | Kvartalsrapport 2020-Q1 |
2020-02-20 | - | Bokslutskommuniké 2019 |
2019-12-17 | - | Extra Bolagsstämma 2019 |
2019-11-19 | - | Kvartalsrapport 2019-Q3 |
2019-08-28 | - | Kvartalsrapport 2019-Q2 |
2019-05-22 | - | X-dag ordinarie utdelning ONCO 0.00 SEK |
2019-05-21 | - | Årsstämma |
2019-05-21 | - | Kvartalsrapport 2019-Q1 |
2019-02-22 | - | Bokslutskommuniké 2018 |
2018-10-26 | - | Kvartalsrapport 2018-Q3 |
2018-07-13 | - | Kvartalsrapport 2018-Q2 |
2018-05-18 | - | X-dag ordinarie utdelning ONCO 0.00 SEK |
2018-05-17 | - | Årsstämma |
2018-05-17 | - | Kvartalsrapport 2018-Q1 |
2018-02-22 | - | Bokslutskommuniké 2017 |
2017-11-15 | - | Kvartalsrapport 2017-Q3 |
2017-08-25 | - | Kvartalsrapport 2017-Q2 |
2017-05-18 | - | Årsstämma |
2017-05-18 | - | Kvartalsrapport 2017-Q1 |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN ONCOPEPTIDES AB (PUBL). SEE ALSO THE SECTION “IMPORTANT INFORMATION” BELOW IN THIS DOCUMENT.
On 21 August 2025, the Board of Directors of Oncopeptides AB (publ) (“Oncopeptides” or the “Company”) (Nasdaq Stockholm: ONCO) resolved, by virtue of the authorization from the Annual General Meeting on 22 May 2025, to carry out a rights issue of approximately SEK 150 million (the “Rights Issue”). At the time of the announcement, the Rights Issue was covered by subscription undertakings, subscription intentions and guarantee commitments up to approximately 87 percent, corresponding to SEK 130 million. The Company has now received additional guarantee commitments of approximately SEK 20 million (the “New Guarantee Commitments”) which entails that subscription undertakings and guarantee commitments cover 100 percent of the Rights Issue. The New Guarantee Commitments are so-called top guarantees.
For the New Guarantee Commitments, cash compensation is paid of 8 percent of the guaranteed amount, which also corresponds to the guarantee compensation for the guarantee commitments previously entered into. The New Guarantee Commitments secure the SEK 20 million which was not covered by previous undertakings, which results in a fully guaranteed Rights Issue.
As communicated in the press release on 21 August 2025, certain board members and senior executives intended to enter into binding subscription undertakings following the publication of the Company’s interim report for the second quarter of 2025 on 21 August 2025. The binding subscription undertakings have been entered into.
Neither the New Guarantee Commitments nor the previous guarantee commitments or subscription undertakings are secured by bank guarantee, blocked funds, pledges or similar arrangements.
“Since announcing the rights issue, we have received positive feedback from investors including an opportunity to guarantee the remaining SEK 20 million. To ensure the rights issue becomes fully subscribed, the company has therefor decided to enter into these additional guarantee commitments.” says Sofia Heigis, CEO of Oncopeptides. “We are grateful for the positive reactions we have received and remain fully committed to continuing our hard work to deliver strong results.”
Disclosure document
Full terms of the Rights Issue and certain information about the Company will be presented in a disclosure document in accordance with Article 1.4 db of the Regulation (EU) 2017/1129 of the European Parliament and of the Council (the “Prospectus Regulation”). The disclosure document, prepared in accordance with Annex IX to the Prospectus Regulation, is expected to be published on or around 28 August 2025.
For more information, please contact:
David Augustsson, Director of IR and Communications, Oncopeptides AB (publ)
E-mail: ir@oncopeptides.com
Cell phone: +46 76 229 38 68
The information was submitted for publication, through the agency of the contact person above, on 25 August 2025 at 20:40 (CEST).
About Oncopeptides
Oncopeptides is a Swedish biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers.
The company uses its proprietary Peptide Drug Conjugate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East and Africa and elsewhere.
Oncopeptides is also developing several new compounds based on its two proprietary technology platforms PDC and SPiKE.
The company was founded in 2000, has about 80 employees with operations in Sweden, Germany, Austria, Spain and Italy. Oncopeptides is listed on Nasdaq Stockholm with the ticker ONCO.
For more information see: www.oncopeptides.com
Important Information
Publication, release, or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where the press release has been made public or distributed should be informed of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer or solicitation to buy or subscribe for any securities in Oncopeptides AB (publ) in any jurisdiction, either from Oncopeptides AB (publ) or from anyone else.
This press release is not a prospectus according to the definition in Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. A disclosure document prepared in accordance with Article 1.4 db and Annex IX of the Prospectus Regulation regarding the Rights Issue described in this press release will be prepared and published by the Company prior to the commencing of the subscription period.
This press release does not constitute an offer or solicitation to buy or subscribe for securities in the United States. The securities mentioned herein may not be sold in the United States without registration, or without an exemption from registration, under the U.S. Securities Act from 1933 (“Securities Act”), and may not be offered or sold within the United States without being registered, covered by an exemption from, or part of a transaction that is not subject to the registration requirements according to the Securities Act. There is no intention to register any securities mentioned herein in the United States or to issue a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, wholly or in part, in or to Australia, Hong Kong, Israel, Japan, Canada, New Zealand, Singapore, South Africa, Switzerland, the United States or any other jurisdiction where the release, publication or distribution of this information would violate current rules or where such an action is subject to legal restrictions or would require additional registration or other measures beyond those that follow from Swedish law. Actions in contravention of this instruction may constitute a violation of applicable securities legislation.
Please note that an investment in the Company is subject to regulation under the Foreign Direct Investment Act (2023:560), which requires investors, under certain conditions, to notify and obtain approval from the Swedish Inspectorate for Strategic Products. Investors should make their own assessment of whether a notification obligation exists before making any investment decision.
Forward-looking statements
This press release contains forward-looking statements related to the Company's intentions, estimates or expectations with regard to the Company's future results, financial position, liquidity, development, outlook, estimated growth, strategies and opportunities as well as the markets in which the Company is active. Forward-looking statements are statements that do not refer to historical facts and can be identified by the use of terms such as “believes”, “expects”, “anticipates”, “intends”, “estimates”, “will”, “may”, “implies”, “should”, “could” and, in each case, their negative, or comparable terminology. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on further assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there is no guarantee that they will occur or that they are correct. Since these assumptions are based on assumptions or estimates and involve risks and uncertainties, actual results or outcomes, for many different reasons, may differ materially from those what is stated in the forward-looking statements. Due to such risks, uncertainties, eventualities and other significant factors, actual events may differ materially from the expectations that expressly or implicitly are contained in this press release through the forward-looking statements. The Company does not guarantee that the assumptions which serve as a basis for the forward-looking statements in this press release are correct, and each reader of the press release should not rely on the forward-looking statements in this press release. The information, opinions and forward-looking statements that expressly or implicitly are stated herein are provided only as of the date of this press release and may change. Neither the Company nor any other party will review, update, confirm or publicly announce any revision of any forward-looking statement to reflect events that occur or circumstances that arise with respect to the contents of this press release, beyond what is required by law or Nasdaq Stockholm Rulebook.
Potential investors should not put undue trust in the forward-looking statements herein, and potential investors are strongly recommended to read the sections in the disclosure document that include a more detailed description of the factors that can affect the Company’s business and its associated market.